Oncolytics Biotech Inc is a biotechnology company focused on developing innovative cancer therapies using a proprietary virus-based approach
The company’s leading product candidate is a proprietary oncolytic virus designed to selectively target and destroy cancer cells while sparing normal healthy tissue. By harnessing the power of the immune system in combination with the virus, Oncolytics aims to create more effective treatment options for various types of cancer, ultimately enhancing patient outcomes. The company is actively involved in clinical trials to evaluate the safety and efficacy of its treatments, contributing to the advancement of cancer care.
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQSGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Gainers Aeglea BioTherapeutics, Inc. (NASDAQAGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private investment positions.
Companies Reporting Before The Bell • CNH Industrial (NYSECNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
